172 related articles for article (PubMed ID: 30967636)
21. Fbxo6 confers drug-sensitization to cisplatin via inhibiting the activation of Chk1 in non-small cell lung cancer.
Cai L; Li J; Zhao J; Guo Y; Xie M; Zhang X; Wang L; Tian H; Li A; Li Q; Miao Y
FEBS Lett; 2019 Jul; 593(14):1827-1836. PubMed ID: 31140586
[TBL] [Abstract][Full Text] [Related]
22. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
23. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
Cortés-Sempere M; de Miguel MP; Pernía O; Rodriguez C; de Castro Carpeño J; Nistal M; Conde E; López-Ríos F; Belda-Iniesta C; Perona R; Ibanez de Caceres I
Oncogene; 2013 Mar; 32(10):1274-83. PubMed ID: 22543588
[TBL] [Abstract][Full Text] [Related]
24. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
25. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
[TBL] [Abstract][Full Text] [Related]
26. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
27. SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer.
Shen L; Yang M; Lin Q; Zhang Z; Miao C; Zhu B
Oncol Rep; 2016 May; 35(5):2561-8. PubMed ID: 26985856
[TBL] [Abstract][Full Text] [Related]
28. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells.
Agger K; Miyagi S; Pedersen MT; Kooistra SM; Johansen JV; Helin K
Genes Dev; 2016 Jun; 30(11):1278-88. PubMed ID: 27257215
[TBL] [Abstract][Full Text] [Related]
29. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
30. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
[TBL] [Abstract][Full Text] [Related]
31. ZNF300 promotes chemoresistance and aggressive behaviour in non-small-cell lung cancer.
Yu S; Ao Z; Wu Y; Song L; Zhang P; Li X; Liu M; Qian P; Zhang R; Li X; Chen Y; Wang X; Wang X; Ruan X; Qian G; Ji F
Cell Prolif; 2020 Nov; 53(11):e12924. PubMed ID: 33078469
[TBL] [Abstract][Full Text] [Related]
32. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
[TBL] [Abstract][Full Text] [Related]
33. Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment.
Eriksson M; Hååg P; Brzozowska B; Lipka M; Lisowska H; Lewensohn R; Wojcik A; Viktorsson K; Lundholm L
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):174-187. PubMed ID: 29107335
[TBL] [Abstract][Full Text] [Related]
34. The molecular landscape of histone lysine methyltransferases and demethylases in non-small cell lung cancer.
Li J; Tao X; Shen J; Liu L; Zhao Q; Ma Y; Tao Z; Zhang Y; Ding B; Xiao Z
Int J Med Sci; 2019; 16(7):922-930. PubMed ID: 31341405
[No Abstract] [Full Text] [Related]
35. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
36. High expression of Rad51c predicts poor prognostic outcome and induces cell resistance to cisplatin and radiation in non-small cell lung cancer.
Chen X; Qian D; Cheng J; Guan Y; Zhang B; Ding X; Zeng J; Chen X; Er P; Zhang F; Zhao N; Chen X; Zhao L; Yuan Z; Pang Q; Wang P
Tumour Biol; 2016 Oct; 37(10):13489-13498. PubMed ID: 27465554
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines.
Song L; Cui Z; Guo X
Acta Biochim Biophys Sin (Shanghai); 2020 Sep; 52(9):944-953. PubMed ID: 32716023
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
39. Diversity within the JMJD2 histone demethylase family.
Shin S; Janknecht R
Biochem Biophys Res Commun; 2007 Feb; 353(4):973-7. PubMed ID: 17207460
[TBL] [Abstract][Full Text] [Related]
40. DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines.
Salim H; Zong D; Hååg P; Novak M; Mörk B; Lewensohn R; Lundholm L; Viktorsson K
BMC Cancer; 2015 Sep; 15():628. PubMed ID: 26353782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
